Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?

Moderna (MRNA) has just been added to the NASDAQ-100 Index. This move places the biotech company alongside some of the largest non-financial companies on the exchange and is drawing fresh attention to its shares. Recent trading has been strong, with Moderna’s share price delivering a 42.14% 1 month gain and a very large year to date share price return. The 1 year total shareholder return is also very large, pointing to powerful momentum following this NASDAQ-100 inclusion. See how Moderna’s...